Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Dr. Attila Endre Pavlath Joins the Board of Directors of ComInnex Inc.

Published: Saturday, August 09, 2014
Last Updated: Saturday, August 09, 2014
Bookmark and Share
Dr. Pavlath’s achievements recognized by ACS at the 248th National Meeting & Exposition in San Francisco.

ComInnex, Inc. has announced that Dr. Attila Endre Pavlath joined its Board of Directors.

Dr. Attila Endre Pavlath, a well known scientist and former ACS president will bring his strategic experience into the governing body of ComInnex. Dr. Pavlath’s 6 decades of achievements are also recognized by the American Chemical Society at a dedicated session at the ACS 248th National Meeting & Exposition in San Francisco on August 12th , 2014 at 8:00 am. (ww.acs.org).

ComInnex is a chemistry and medicinal chemistry service organization with strong interest and background in the development of chemical technologies that enables its partners to access novel chemical space and intellectual property. Its current technology innovation platform focuses on the development of synthetic tools towards novel non-flat fragment-like and lead-like molecules for lead identification and medicinal chemistry. To this end the company recently introduced its Smartdiversity™ platform that rapidly creates new IP space for medicinal chemistry.

ComInnex technologies enable the company to penetrate chemical space not easily reachable by traditional laboratory techniques and develop unique and patentable molecular frameworks of high value for the pharmaceutical, agrochemical and chemical industries.

Dr. Ferenc Darvas, President and Chairman of ComInnex commented that “We are proud that Dr. Pavlath joins our Governing Board. We believe that his experience and significant
achievements will be a great asset for the company and will help expand our value added innovative portfolio of offerings.”

Dr. Pavlath added that “I am glad that I could join such a dynamic and innovative company like ComInnex at the governing level and join the experienced industry veterans in the management and Board level such as Dr. Ferenc Darvas, Dr. Gergely Makara and Dr. Laszlo Urge. I believe that together we will create and execute a strategy that will benefit customers significantly and keep ComInnex in the forefront of innovation.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Spero Therapeutics Announces $30 Million Series B Preferred Financing
Company has announced financing of $30 million to support development of novel therapies to treat gram-negative bacterial infections.
Keeping Tumor Growth at Bay
Engineers at Washington University in St. Louis found a way to keep a cancerous tumor from growing by using nanoparticles of the main ingredient in common antacid tablets.
Future of Medicine Could be Found in a Tiny Crystal Ball
A Drexel University materials scientist has discovered a way to grow a crystal ball in a lab. Not the kind that soothsayers use to predict the future, but a microscopic version that could be used to encapsulate medication in a way that would allow it to deliver its curative payload more effectively inside the body.
Improving Delivery of Poorly Soluble Drugs Using Nanoparticles
A technology that could forever change the delivery of drugs is undergoing evaluation by the Technology Evaluation Consortium™ (TEC). Developed by researchers at Northeastern University, the technology is capable of creating nanoparticle structures that could deliver drugs into the bloodstream orally – despite the fact that they are normally poorly soluble.
Faster Drug Discovery?
Startup develops more cost-effective test for assessing how cells respond to chemicals.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Nanoparticles Deliver Tumor Suppressors to Damaged Livers
UT Southwestern Medical Center chemists have successfully used synthetic nanoparticles to deliver tumor-suppressing therapies to diseased livers with cancer, an important hurdle scientists have been struggling to conquer.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
A New Type of Anticancer Agent
Success in the development of a ?-tubulin specific inhibitor.
Nanoparticles Proven Effective Against Antibiotic-Resistant “Superbugs”
In the ever-escalating evolutionary battle with drug-resistant bacteria, humans may soon have a leg up thanks to adaptive, light-activated nanotherapy developed by researchers at the University of Colorado Boulder.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!